Overview

A Study to Evaluate the Safety, Pharmacokinetics, and Antitumor Activity of AK127 in Combination With AK104 in Advanced and Metastatic Solid Tumours

Status:
Recruiting
Trial end date:
2025-04-07
Target enrollment:
Participant gender:
Summary
A Phase 1 study to evaluate the safety, tolerability, PK, immunogenicity, pharmacodynamics, and preliminary antitumor activity of AK127 in combination with AK104.
Phase:
Early Phase 1
Details
Lead Sponsor:
Akesobio Australia Pty Ltd